Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hsiehchen

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
JCO Oncology Practice|June 21, 2021
Clinical Efficiency and Safety Outcomes of Virtual Care for Oncology Patients During the COVID-19 PandemicDavid Hsiehchen, Maishara Muquith, Waqas Haque, et al.
JAMA Network Open|February 25, 2025
Complete Response to Immunotherapy in Patients With Hepatocellular CarcinomaMir Lim, Magdalena Espinoza, Yi-Hsiang Huang, et al.
Science Advances|December 5, 2020
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of <i>MYBBP1A</i> can be preferentially targeted by PARP inhibitorsAntony Hsieh, Jason R Pitarresi, Jonathan Lerner, et al.
Hepatology (Baltimore, Md.)|May 31, 2023
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinomaMir Lim, Maishara Muquith, Bernadette Miramontes, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 26, 2020
Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular CarcinomaAndrew S Chung, Marcel Mettlen, Debolina Ganguly, et al.
Clinical Lung Cancer|October 17, 2022
Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy EraAmrit S Gonugunta, Mitchell S Von Itzstein, David Hsiehchen, et al.
Nature Communications|December 3, 2022
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancersDavid Hsiehchen, Leslie Bucheit, Dong Yang, et al.
Cell Reports. Medicine|July 18, 2020
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation BurdenDavid Hsiehchen, Antony Hsieh, Robert M Samstein, et al.
Disease Models & Mechanisms|July 24, 2025
Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAsGianna Maggiore, Meng-Hsiung Hsieh, Amaey Bellary, et al.
Cancers|November 11, 2022
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint InhibitorsKrista Y Chen, Aleksandra Popovic, David Hsiehchen, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
JCO Oncology Practice|June 21, 2021
Clinical Efficiency and Safety Outcomes of Virtual Care for Oncology Patients During the COVID-19 PandemicDavid Hsiehchen, Maishara Muquith, Waqas Haque, et al.
JAMA Network Open|February 25, 2025
Complete Response to Immunotherapy in Patients With Hepatocellular CarcinomaMir Lim, Magdalena Espinoza, Yi-Hsiang Huang, et al.
Science Advances|December 5, 2020
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of <i>MYBBP1A</i> can be preferentially targeted by PARP inhibitorsAntony Hsieh, Jason R Pitarresi, Jonathan Lerner, et al.
Hepatology (Baltimore, Md.)|May 31, 2023
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinomaMir Lim, Maishara Muquith, Bernadette Miramontes, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 26, 2020
Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular CarcinomaAndrew S Chung, Marcel Mettlen, Debolina Ganguly, et al.
Clinical Lung Cancer|October 17, 2022
Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy EraAmrit S Gonugunta, Mitchell S Von Itzstein, David Hsiehchen, et al.
Nature Communications|December 3, 2022
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancersDavid Hsiehchen, Leslie Bucheit, Dong Yang, et al.
Cell Reports. Medicine|July 18, 2020
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation BurdenDavid Hsiehchen, Antony Hsieh, Robert M Samstein, et al.
Disease Models & Mechanisms|July 24, 2025
Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAsGianna Maggiore, Meng-Hsiung Hsieh, Amaey Bellary, et al.
Cancers|November 11, 2022
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint InhibitorsKrista Y Chen, Aleksandra Popovic, David Hsiehchen, et al.
Pageof 7